In a landmark achievement for medical research in the United Arab Emirates, Prof. Ayman W. El-Hattab and his team at Burjeel Medical City in Abu Dhabi have played a pivotal role in identifying and naming El-Hattab-Schmidts syndrome, a rare genetic neurodevelopmental disorder primarily affecting children's brain development and muscle function. This discovery underscores the UAE's growing prominence in global genetics and rare disease research, providing crucial answers for families worldwide who have long grappled with undiagnosed cases.
El-Hattab-Schmidts syndrome manifests early in life, disrupting normal brain maturation and leading to a cascade of challenges that impact daily functioning. Children with this condition often present with profound developmental delays that become evident in infancy, setting the stage for lifelong support needs. The formal recognition of this syndrome not only honors Prof. El-Hattab's contributions but also paves the way for targeted diagnostics and interventions.
The Clinical Profile of El-Hattab-Schmidts Syndrome
At its core, El-Hattab-Schmidts syndrome is characterized by global developmental delay and intellectual disability, affecting cognitive, motor, and social milestones. Infants typically exhibit severe hypotonia, or low muscle tone, resulting in a 'floppy' appearance and significant feeding difficulties due to oropharyngeal dysphagia, recurrent vomiting, drooling, and choking risks. As these children grow, additional symptoms emerge, including learning disabilities, poor coordination, and in some cases, seizures such as generalized clonic or myoclonic types, often triggered by fever.
Ophthalmologic issues are common, with strabismus, nystagmus, and optic atrophy impairing vision and potentially requiring low-vision aids. Distinctive facial features include highly arched and thick eyebrows, thick vermilion of the lips, a broad nasal bridge, and low-set ears, aiding clinical recognition. Neuroimaging reveals structural anomalies like delayed myelination, wavy ventricular outlines, enlarged ventricles, corpus callosum abnormalities, and cerebellar hypoplasia.
Respiratory complications, including apnea, recurrent infections, and laryngomalacia, pose immediate threats, while cardiac findings such as left ventricular hypertrophy, noncompaction cardiomyopathy, or atrial septal defects necessitate ongoing cardiology monitoring. Behavioral challenges like aggression, ADHD-like symptoms, stereotypies, and bruxism further complicate care. Less frequent but notable are hepatosplenomegaly, hypertrichosis, and hyporeflexia. Prognosis varies; while survival into adulthood is possible, early mortality from infections or cardiorespiratory issues has been reported in some of the 24 documented cases.
Genetic Underpinnings: The Role of PPP1R21 Variants
The disorder stems from biallelic pathogenic variants in the PPP1R21 gene on chromosome 2p16.3, which encodes protein phosphatase 1 regulatory subunit 21. This protein is essential for early endosomal maturation and trafficking, facilitating the degradation of dysfunctional cellular components via autophagosomes. Loss-of-function mutations—primarily missense and nonsense variants—disrupt these processes, leading to the syndrome's hallmark neurodevelopmental deficits.
Autosomal recessive inheritance means both parents are asymptomatic carriers, with a 25% recurrence risk per pregnancy. No genotype-phenotype correlations have been established, and deletions/duplications are unreported. Highly consanguineous populations, prevalent in parts of the Arab world including the UAE, show higher incidence, explaining many reported cases among individuals of Arab descent. Genetic testing via exome or genome sequencing confirms diagnosis, detecting nearly all variants.
The Discovery Journey at Burjeel Medical City
The breakthrough traces back to 2018 when Prof. El-Hattab's team evaluated three Emirati children presenting with overlapping unexplained symptoms. Advanced genetic sequencing revealed novel PPP1R21 variants, prompting the hypothesis of a new syndrome. 'The similarity of the clinical features and the biological importance of the gene suggested we were looking at a new syndrome,' Prof. El-Hattab recalled.
Independent reports soon followed, including a 2019 publication by Dr. Jonathan Schmidts' group, culminating in the syndrome's eponymous naming. This multinational effort, culminating in the January 2026 GeneReviews entry, formalized its recognition. Burjeel Medical City's Genetics and Rare Disease Center, directed by Prof. El-Hattab since its 2025 launch, evaluates 600-800 patients monthly, fostering such discoveries.
Prof. Ayman W. El-Hattab: A Pioneer in UAE Genetics
Prof. El-Hattab, originally from Jordan and triple-board-certified in Pediatrics, Clinical Genetics, and Biochemical Genetics by American boards, has identified over ten novel syndromes. This marks the third bearing his name, highlighting his expertise. As Director of Burjeel Medical City's center, he champions advanced genomic tools, stating, 'Advances in genetic testing are helping us uncover more conditions and provide answers to families.' His work aligns with UAE's vision for healthcare innovation.
His message to affected families: 'Do not give up. With rapid progress, more diagnoses are possible.'Learn more in the official GeneReviews summary.
Photo by Pawel Czerwinski on Unsplash
Diagnosing El-Hattab-Schmidts Syndrome: From Suspicion to Confirmation
Suspicion arises from the constellation of hypotonia, developmental delay, coarse features, and multi-system involvement in consanguineous families. No consensus criteria exist, but exome/genome sequencing is the gold standard, often as first-tier for undiagnosed neurodevelopmental disorders. Multigene panels may suffice if PPP1R21 is included. Brain MRI and EEG support evaluation, revealing characteristic anomalies.
Early diagnosis is critical; it ends diagnostic odysseys, informs management, and enables reproductive planning via preimplantation genetic diagnosis (PGD) during IVF.
Management Strategies and Multidisciplinary Care
No cure exists, but multidisciplinary interventions optimize outcomes. Early developmental therapies address delays; feeding support, including gastrostomy, combats malnutrition. Ophthalmologic care manages vision; pulmonology handles respiratory risks; cardiology monitors hearts; anti-seizure meds control epilepsy. Behavioral therapies target ADHD and aggression; social services aid families.
Surveillance includes regular developmental assessments, eye/respiratory exams, annual echoes, and EEGs. Transitional planning ensures adult care continuity. Prof. El-Hattab emphasizes early intervention's role in quality-of-life gains.
UAE's Ascendance in Rare Disease Research
The UAE, with facilities like Burjeel Medical City, leads MENA in genomics. High consanguinity rates (up to 50% in some groups) drive rare recessive disorder prevalence, but advanced testing reverses misdiagnosis trends. Collaborations with global centers amplify impact, positioning UAE as a hub for pediatric genetics.
Burjeel's center exemplifies integrated care, combining diagnostics, research, and counseling.
Global Perspective and Research Frontiers
With only 24 cases reported, prevalence remains unknown but likely underdiagnosed. Initial reports (Suleiman 2018, Rehman 2019) built the evidence base. Future research targets PPP1R21 function restoration, gene therapies, and phenotype expansion. Clinical trials (none specific yet) could emerge via platforms like ClinicalTrials.gov.
Empowering Families: Genetic Counseling and Hope
Genetic counseling clarifies 25% recurrence risks, offering carrier testing and PGD. UAE families benefit from accessible testing, reducing stigma and enabling informed choices. Support groups and resources foster resilience.
Prof. El-Hattab's discoveries inspire hope, transforming mysteries into manageable realities.
Photo by iMattSmart on Unsplash
Future Outlook: Therapeutic Horizons
Understanding PPP1R21's endosomal role opens doors to autophagy-enhancing drugs. UAE's investment in biotech promises trials. Early diagnosis via newborn screening could become feasible, preventing complications.
This syndrome's elucidation exemplifies precision medicine's power, heralding better futures for rare disease patients globally.